$0.6826
0.0236[3.58%]
At close: Apr 26
$0.6826
0[0.00%]
After Hours: 8:14AM EDT
Chemomab Therapeutics
(NASDAQ:CMMB)Latest News for Chemomab Therapeutics Stock (NASDAQ:CMMB)
Chemomab Therapeutics Stock (NASDAQ: CMMB)
Categories: All
Thursday, April 18, 2024
- Chemomab Therapeutics shares are trading higher after the company announced the publication of a new study reinforcing the clinical association of its CCL24 target with disease severity and mortality in patients with systemic sclerosis.Benzinga Newsdesk - Apr 18, 2024, 12:59PM
- Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target with Disease Severity and Mortality In Systemic SclerosisBenzinga Newsdesk - Apr 18, 2024, 7:11AM
Monday, March 25, 2024
- Chemomab shares are trading higher after the company was granted a new European patent for CM-101.Benzinga Newsdesk - Mar 25, 2024, 7:19AM
- Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisBenzinga Newsdesk - Mar 25, 2024, 7:09AM
Friday, March 08, 2024
Thursday, March 07, 2024
- Cemomab Therapeutics shares are trading higher after the company reported a year-over-year increase in Q4 EPS results.Benzinga Newsdesk - Mar 7, 2024, 1:13PM
- Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoYBenzinga Newsdesk - Mar 7, 2024, 7:06AM
- Earnings Scheduled For March 7, 2024Benzinga Insights - Mar 7, 2024, 4:49AM
Thursday, February 22, 2024
Wednesday, February 21, 2024
Tuesday, February 20, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Feb 20, 2024, 4:31PM
- What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?Vandana Singh - Feb 20, 2024, 12:30PM
- Chemomab Wins New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesBenzinga Newsdesk - Feb 20, 2024, 7:10AM
Thursday, January 18, 2024
Wednesday, January 03, 2024
Tuesday, December 19, 2023
Thursday, November 16, 2023
- Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Nov 16, 2023, 1:11PM
- Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving PremarketLisa Levin - Nov 16, 2023, 8:08AM
- Chemomab Therapeutics Reported On Its Poster Presentation At The American College Of Rheumatology Convergence 2023 Conference Highlighting Key Role Of Its CCL24 Target In The Pathogenesis Of Systemic SclerosisBenzinga Newsdesk - Nov 16, 2023, 7:19AM
Wednesday, November 15, 2023
- Crude Oil Falls 2%; TJX Issues Weak Earnings OutlookLisa Levin - Nov 15, 2023, 2:30PM
- Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Nov 15, 2023, 2:04PM
- Chemomab Therapeutics shares are trading higher after the company announced it received FDA fast track designation for CM-101 for the treatment of primary sclerosing cholangitis.Benzinga Newsdesk - Nov 15, 2023, 1:46PM
- US Stocks Gain; Producer Prices Fall In OctoberLisa Levin - Nov 15, 2023, 9:57AM
- Why is Liver Disease Focused Chemomab Stock Trading Higher Today?Vandana Singh - Nov 15, 2023, 8:29AM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Nov 15, 2023, 8:06AM
- Chemomab Therapeutics Receives FDA Fast Track Designation For CM-101 For Treatment Of Primary Sclerosing CholangitisBenzinga Newsdesk - Nov 15, 2023, 7:04AM
Thursday, November 09, 2023
Monday, November 06, 2023
Monday, October 16, 2023
Friday, October 06, 2023
Monday, August 14, 2023
Thursday, June 22, 2023
Wednesday, June 21, 2023
- High-Impact Movers for June 21stBenzinga Newsdesk - Jun 21, 2023, 8:41AM
- What's Going On With Chemomab Therapeutics Stock TodayVandana Singh - Jun 21, 2023, 8:35AM
- Chemomab Therapeutics shares are trading higher after the company reported data from secondary analysis of Phase 2a liver fibrosis trial assessing CM-101.Benzinga Newsdesk - Jun 21, 2023, 7:20AM
- Chemomab Therapeutics Reports Data From Secondary Analysis Of Phase 2a Liver Fibrosis Trial In NASH Patients Showing Treatment With Cm-101 Improves Additional Biomarkers Of Fibrosis And Inflammation, Reinforcing And Extending Initial Study ResultsBenzinga Newsdesk - Jun 21, 2023, 7:08AM